Healthy Volunteers Curcumin Nanocurcumin Pharmacokinetics Safety
Conditions
Interventions
-
50 mg of WellCap Kaminn
-
Single dose,
dose escalation,-
100 mg of WellCap Kaminn
-
200 mg of WellCap Kaminn
-
Experimental Drug,Experimental Drug,Experimental Drug
WellCap Kaminn (nanocurcumin) dose 1 ,WellCap Kaminn (nanocurcumin) dose 2,WellCap Kaminn (nanocurcumin) dose 3
Sponsors
Khon Kaen University
Welltech Biotechnology co. ltd
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: - healthy volunteer - Age between 18 - 45 years old - Signed informed consent
Exclusion criteria
Exclusion criteria: 1. Woman who are pregnancy, breastfeeding or planning to become pregnant during the course of the trial 2. There are medical history that allergic turmeric 3. Eating natural product containing turmeric or curcumin, or foods that contain turmeric or curcumin within 14 days before joining the research project 4. Patient who have a congenital disease or undergoing treatment with immunosuppressants, antibiotics, anti-inflammatory drugs, or diagnosed with chronic or immunocompromised diseases such as high blood pressure, diabetes, hepatitis, kidney disease etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety and tolerability of increasing doses of WellCap Kaminn in healthy subjects 48 hour adverse events, vital signs and adverse events, vital signs and laboratory assessments | — |
Secondary
| Measure | Time frame |
|---|---|
| Investigation of the pharmacokinetics of WellCap Kaminn in healthly subject 48 hour Area Under the Curve, Maximum Concentration and ime until maximum concentration | — |
Countries
Thailand
Contacts
Public ContactSomchai Pinlaor
Faculty of medicine, Khon Kaen University
Outcome results
None listed